Podcasts about san diego center

Join us on We Heart Therapy as host Dr. Belle, PhD, LMFT, a Certified EFT Supervisor & Therapist, dives deep into the intricacies of working with betrayal trauma in couples therapy. In this insightful discussion, Dr. Belle is joined by the esteemed Dr. Lisa Palmer-Olsen, an ICEEFT Certified EFT Trainer from the San Diego Center for EFT. Together, they explore the transformative power of Emotionally Focused Therapy (EFT) in helping couples navigate and heal from the wounds of betrayal. Discover expert techniques and compassionate approaches that can pave the way for renewed trust and deeper connection. Don't miss this essential conversation for therapists and couples alike!   ‪@Wehearttherapy‬   For more information on EFT, to get trained in EFT or to find an EFT therapist in your area, please visit: https://www.iceeft.com or https://www.drsuejohnson.com   For more information on special guest Dr. Lisa Palmer-Olsen please visit: https://renovasandiego.com or https://drlisapalmerolsen.com or email her at: lisapalmerolsen@gmail.com   For more information on your host, or if you're interested in working with Dr. Belle in a private couples therapy intensive, please visit: https://www.lasvegasmarriagecounselin... https://www.DrBelle.com https://www.WeHeartTherapy.com   For EFT Training in Las Vegas hosted by Dr. Belle, visit: https://www.snveft.com

What if the key to unlocking a world of clear vision, improved focus, and even better brain function lies not in stronger prescriptions, but in a completely different approach to eye care?In this episode we dive deep into the fascinating world of vision therapy and prism glasses with Dr. Justin, an optometrist specializing in this revolutionary field.  Dr. Justin reveals how vision problems go far beyond just blurry sight, and can actually impact everything from learning and behavior in children to overall well-being in adults.  Learn how subtle adjustments in your vision, achieved through specialized techniques and even prism glasses, can unlock a new level of health and performance.  Don't miss this eye-opening episode (pun intended!) and take the first step towards a healthier, clearer you!Highlights:How vision therapy can address common issues like eye teaming problems, focusing difficulties, and even dyslexia in children.The surprising link between screen time and vision health, and strategies to combat the negative effects of our digital world.Why a holistic approach to vision care is essential, and how incorporating movement assessments and other therapies can lead to powerful results.Resources MentionedWebsite | https://sandiegocenterforvisioncare.com/justin-matsuura-od/About the Guest:Dr. Justin S. Matsuura graduated from the University of California Irvine with a Bachelor of Science degree in Biological Sciences. During his undergraduate work, Dr. Matsuura was a member of UCI's pre-optometry club and volunteered at local private practices during his spare time.Dr. Matsuura received his Doctor of Optometry degree from Southern California College of Optometry at Marshall B. Ketchum University. His clinical externships were completed at the University Eye Center at Ketchum Health in Anaheim, University Eye Center Los Angeles, Southern Arizona VA Health Care System in Tucson, AZ, and the San Diego Center for Vision Care.As a result of his education and clinical training, Dr. Matsuura is licensed to use and prescribe therapeutic pharmaceutical agents, diagnose, treat, and manage patients with glaucoma, and perform lacrimal irrigation/dilation procedures in addition to providing comprehensive and specialty eye examinations for patients of all ages. He is also well trained and up to date with the most recent advances in myopia control, ocular disease diagnosis/management, specialty contact lenses, refractive surgery, primary care optometry, pediatric optometry, vision therapy, sports vision and neuro-rehabilitation optometry.Dr. Matsuura is also an active member in the professional optometric community as he is a member of the American Optometric Association and the California Optometric Association.Dr. Matsuura looks forward to providing quality care and service to those in the greater San Diego area while also developing strong relationships with all patients, parents, educators, and healthcare professionals.

Hosts Jim DeRogatis and Greg Kot talk with Ira Robbins, founder of Trouser Press magazine which inspired a generation of underground music writers. Plus, the hosts review new music from Billie Eilish and Shellac.--Get Exclusive NordVPN deal here → https://nordvpn.com/soundops It's risk-free with Nord's 30-day money-back guarantee!--Become a member on Patreon: https://bit.ly/3slWZvcSign up for our newsletter: https://bit.ly/3eEvRnGMake a donation via PayPal: https://bit.ly/3dmt9lUSend us a Voice Memo: Desktop: bit.ly/2RyD5Ah Mobile: sayhi.chat/soundopsJoin our Facebook Group: https://bit.ly/3sivr9T--Featured Songs:Billie Eilish, "Skinny," Hit Me Hard and Soft, Interscope, 2024The Beatles, "With A Little Help From My Friends," Sgt. Pepper's Lonely Hearts Club Band, Parlophone, 1966Billie Eilish, "Ocean Eyes," Don't Smile at Me, Interscope, 2017Billie Eilish, "Lunch," Hit Me Hard and Soft, Interscope, 2024Billie Eilish, "Bury A Friend," When We All Fall Asleep, Where Do We Go?, Interscope, 2019Billie Eilish, "The Greatest," Hit Me Hard and Soft, Interscope, 2024Billie Eilish, "Blue," Hit Me Hard and Soft, Interscope, 2024Shellac, "Scabby the Rat," To All Trains, Touch and Go, 2024Shellac, "I Don't Fear Hell," To All Trains, Touch and Go, 2024Shellac, "Tattoos," To All Trains, Touch and Go, 2024Rory Gallagher, "A Million Miles Away (Live at The San Diego Center, CA, USA 1974)," Live In San Diego '74, UMC, 2022Tucky Buzzard, "Run in the Morning," Buzzard, Purple, 1973The Who, "A Quick One, While He's Away," A Quick One, Reaction, 1966Camel, "Never Let Go (Live at Hammersmith Odeon)," A Live Record, Deram, 1978The Bonzo Doo-Dah Dog Band, "The Trouser Press," The Doughnut in Granny's Greenhouse, Liberty, 1968Carole King, "I Feel the Earth Move," Tapestry, Ode, 1975See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Navigating the challenging waters of divorce or betrayal within a relationship can be an incredibly tough journey. It's a time when seeking support becomes crucial, and for many, individual or couples therapy becomes a lifeline. However, the impact of a couple's distress extends far beyond the partners involved. They often overlook how their struggles reverberate throughout the entire family. In this episode, we dive into the critical importance of considering therapy for the entire family system. This episode offers strategies for gaining a deeper understanding of how family members at various developmental stages are affected, and how to create a safe space for open communication and emotional support within the family, prioritizing the children's development amidst distress. Kathryn de Bruin is a Marriage and Family Therapist, Certified Emotional Focused Therapy Trainer and Supervisor, and Registered Play Therapist Supervisor.  She has a full-time private practice in San Diego, CA where she works with children and families.  Kathryn teaches Play Therapy at the University of California, San Diego, in the Play Therapy Program. She is a Director for the San Diego Center for EFT, and serves various EFT communities. Lisa Palmer-Olsen, Psy.D. is a licensed Marriage and Family Therapist in San Diego California. She is a Certified EFT Therapist, Trainer, and Supervisor, and is a Founder and one of the Directors of the Emotionally Focused Couples Training and Research Institute at Alliant International University. Lisa completed her dissertation research on how to train and teach Emotionally Focused Couples therapy to professionals. Dr. Sue Johnson, the founder of EFT and Dr. Scott Woolley were part of her dissertation committee. Check out the transcript of this episode on Dr. Jessica Higgin's website. In this episode 5:02 Lisa and Kathryn's journey into supporting couples and families. 10:00 The importance of considering the broader impact within the family system. 15:20 The growing trend of parents seeking comprehensive support. 19:40 Creating new pathways for family connection. 28:04 Creating space for dialogue within the family and seeking community resources to combat isolation. 46:43 Redefining conflict resolution in family law: The role of attachment-based mediation. 48:54 Valuable resources for individuals navigating family therapy and seeking emotional support. Mentioned Emotionally Focused Family Therapy: Restoring Connection and Promoting Resilience (*Amazon Affiliate link) (book) Together: The Healing Power of Human Connection in a Sometimes Lonely World (book) The Good Divorce (*Amazon Affiliate link) (book) Constance Ahrons, Ph.D. EFT Therapist Search ERP 175: How to Heal from an Affair – An Interview with Scott Woolley Connect with Kathryn de Bruin & Dr. Lisa Palmer-Olsen Websites: renovasandiego.com | kathryndebruin.com Podcast: podcasts.apple.com/us/podcast/the-family-express Connect with Dr. Jessica Higgins Facebook: facebook.com/EmpoweredRelationship  Instagram: instagram.com/drjessicahiggins  Podcast: drjessicahiggins.com/podcasts/ Pinterest: pinterest.com/EmpowerRelation  LinkedIn: linkedin.com/in/drjessicahiggins  Twitter: @DrJessHiggins  Website: drjessicahiggins.com   Email: jessica@drjessicahiggins.com If you have a topic you would like me to discuss, please contact me by clicking on the “Ask Dr. Jessica Higgins” button here.  Thank you so much for your interest in improving your relationship.  Also, I would so appreciate your honest rating and review. Please leave a review by clicking here.  Thank you!   *With Amazon Affiliate Links, I may earn a few cents from Amazon, if you purchase the book from this link.  

Dr. Moises Baron, President & CEO of the San Diego Center for Children, chats about the pediatric mental health care crisis; the Center's comprehensive continuum of pediatric mental health and education services; and its success in improving access to mental health care.

In this excellent episode, Nancy and Charles are joined in the studio by Moises Baron, the President and CEO of the San Diego Center for Children.The center provides a wide range of mental health and educational services to children and youth with mental, emotional, and behavioral disorders, spanning ages from 4 to 22, and includes support for families.Hear Moises talks about his nine-year tenure at the center and the upcoming plans for his retirement, emphasizing the positive changes that have occurred during his leadership. He also shares his perspective on the challenges of leading an organization with such a long legacy and the need for transformation to adapt to the changing landscape of pediatric mental health.This episode also delves into the evolving landscape of children's mental health, the impact of the COVID-19 pandemic, increased divorce rates, information overload, and the effects of social media on young minds. There is a recognition of a pediatric mental health crisis, which predates the pandemic and the associated challenges in accessing care. This episode also touches on the significance of fun and play in childhood development and the need for holistic approaches that include arts, physical education, and recreational activities. The San Diego Center for Children's approach focuses on prevention, early intervention, and a continuum of care tailored to individual needs.Listen in as Moises discusses the importance of early identification, early intervention, and improving access to care for children. He emphasizes the need for a strategic, integrated approach to address these challenges effectively, mentioning the state's investment of $4.2 billion in child and youth mental health. The shortage of mental health providers in San Diego is highlighted, along with the necessity to invest in workforce development to ensure that children receive the care they need.An excellent episode on filling gaps in the community with Moises Baron. Here are some other takeaways from the interview:the presence of a pediatric mental health crisis, which predates the COVID-19 pandemic. Factors like increased divorce rates, information overload, and the impact of social media have all contributedThe shortage in mental health providers is a barrier to providing adequate care for children with mental health issues and thus there is a need for investing in workforce developmentThe importance of open conversations about mental health, especially in schools. Destigmatizing mental health discussions can help children feel more comfortable seeking help when they are struggling.the importance of strategic planning to ensure that the influx of resources and investments in pediatric mental health leads to sustainable and effective change.The answers to the rapid-fire questionsAn excellent interview from a passionate gap minder. Thank you, Moises, for your contributions in San Diego, and for joining us on The Gap Minders.Enjoy this episode and be sure to subscribe to the show.If you have any questions or want to contact Nancy or Charles, please send an email to podcast@uwsd.org. Thank you for listening.To learn more about the two social impact organizations making The Gap Minders possible, please visit www.TheGapMinders.org.

In this excellent episode, Nancy and Alicia are joined in the studio by Dr. Ben Maxwell, the Division Chief of Child & Adolescent Psychiatry at Rady Children's Hospital. Rady Children's Hospital is the largest children's hospital in California and plays a crucial role in addressing pediatric mental health.Hear Dr. Maxwell highlight the significant increase in psychiatric emergencies in recent years, with the hospital seeing over 4,700 cases in the last fiscal year, emphasizing the urgent need for mental health support for children and adolescents. This episode also delves into the impact of the COVID-19 pandemic on youth mental health, emphasizing that it exacerbated existing challenges such as social disconnection, stress, and uncertainty.Listen as Dr. Maxwell emphasizes the importance of community collaboration and partnerships with organizations like UC San Diego, San Diego Center for Children, and others to address the crisis effectively. He also discusses efforts to train pediatricians to identify and address mental health concerns in children early on and the need to reduce the stigma surrounding mental health issues. This episode also touches on the importance of social connection and community in promoting mental well-being and how everyone can contribute to building a more connected and supportive society.An excellent episode on filling gaps in the community with Dr. Maxwell. Here are some other takeaways from the interview:The youth mental health crisis and its significant impact on pediatric care at Rady Children's Hospital in San Diego.How the COVID-19 pandemic exacerbated existing mental health challenges among children and adolescents, emphasizing the need for community support.Collaboration with various organizations and training programs for pediatricians are essential strategies to address the crisis effectively.Stigma surrounding mental health issues is gradually diminishing, but there is still much work to be done to ensure early intervention and support.The importance of social connections and community in promoting mental well-being is highlighted, with an emphasis on everyone's role in building a more connected and supportive society.The answers to the rapid-fire questionsAn excellent interview from a passionate gap minder. Thank you, Ben, for your contributions in San Diego, and for joining us on The Gap Minders.Enjoy this episode and be sure to subscribe to the show.If you have any questions or want to contact Nancy or Alicia, please send an email to podcast@uwsd.org. Thank you for listening.To learn more about the two social impact organizations making The Gap Minders possible, please visit www.TheGapMinders.org.

  Slam the Gavel welcomes Lisa Breece Linke, Director Of Operations at PAS Family Advocacy, BT, CDC.  Lisa is a Mental Health professional driven to help others overcome personal obstacles. She is a responsible self-starter who communicates well and is dedicated to improving the well-being of her clients.    Team-oriented Behavioral Specialist with a strong track record of establishing solid relationships with her clients, co-workers and administration and local agencies, Lisa has successfully worked with diverse client population in one-on-one and group settings. Lisa is also a skilled Behavioral Specialist with an expertise in the identification and management of mental illnesses.    We discussed her work at San Diego Center for Children and Residential Care, from there she went into Behavior Therapy which included the Autism community. Our discussion also included the lack of training in Social Workers, Case Workers and Guardian Ad Litem who have very little Child Development background.     Civil Rights Claim Under the Color Of Law was discussed as well as how LexisNexis is used to target minorities. We talked about the Tort Intentional Infliction Of Emotional Distress and how that involves the courts. Great conversation with Lisa Breece Linke.To Reach Lisa:  lisa@pasfamilyadvocacy.com mailto:Admin@PASFamilyAdvocacy.commailto:CFAlawsuit@activist.comPAS Family Advocacy: 858-260-8458Bustin' Chops & Callin' ShotsEach week Josh and Jon sit down to give their take on travel sports and everything in...Listen on: Apple Podcasts SpotifySupport the showSupportshow(https://www.buymeacoffee.com/maryannpetri)http://beentheregotout.com/http://www.dismantlingfamilycourtcorruption.com/

Slam the Gavel welcomes Lisa Breece Linke, Director Of Operations at PAS Family Advocacy, BT, CDC. Lisa is a Mental Health professional driven to help others overcome personal obstacles. She is a responsible self-starter who communicates well and is dedicated to improving the well-being of her clients. Team-oriented Behavioral Specialist with a strong track record of establishing solid relationships with her clients, co-workers and administration and local agencies, Lisa has successfully worked with diverse client population in one-on-one and group settings. Lisa is also a skilled Behavioral Specialist with an expertise in the identification and management of mental illnesses. We discussed her work at San Diego Center for Children and Residential Care, from there she went into Behavior Therapy which included the Autism community. Our discussion also included the lack of training in Social Workers, Case Workers and Guardian Ad Litem who have very little Child Development background. Civil Rights Claim Under the Color Of Law was discussed as well as how LexisNexis is used to target minorities. We talked about the Tort Intentional Infliction Of Emotional Distress and how that involves the courts. Great conversation with Lisa Breece Linke. To Reach Lisa: lisa@pasfamilyadvocacy.com mailto:Admin@PASFamilyAdvocacy.com mailto:CFAlawsuit@activist.com PAS Family Advocacy: 858-260-8458 Support the show Supportshow(https://www.buymeacoffee.com/maryannpetri) http://beentheregotout.com/ http://www.dismantlingfamilycourtcorruption.com/ --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/maryann-petri/support

    Slam the Gavel welcomes Lisa Breece Linke, Director Of Operations at PAS Family Advocacy, BT, CDC.  Lisa is a Mental Health professional driven to help others overcome personal obstacles. She is a responsible self-starter who communicates well and is dedicated to improving the well-being of her clients.    Team-oriented Behavioral Specialist with a strong track record of establishing solid relationships with her clients, co-workers and administration and local agencies, Lisa has successfully worked with diverse client population in one-on-one and group settings. Lisa is also a skilled Behavioral Specialist with an expertise in the identification and management of mental illnesses.    We discussed her work at San Diego Center for Children and Residential Care, from there she went into Behavior Therapy which included the Autism community. Our discussion also included the lack of training in Social Workers, Case Workers and Guardian Ad Litem who have very little Child Development background.     Fascinating discussion included 1997 ASFA, Child Trafficking with over 800,000 children gone missing. The fictitious Family Courts and that the judges are a corporate entity, a registered agent and is insured with indemnity insurance is something all litigants should explore when finding malfeasance in their case.    Advice was given if CPS comes to your door as well and that caseworkers also have their own insurances.      We discussed that all litigants Pro Se or otherwise get the Black's Law Dictionary which Lisa has a free PDF for parents on her web-site.To Reach Lisa:  lisa@pasfamilyadvocacy.com mailto:Admin@PASFamilyAdvocacy.commailto:CFAlawsuit@activist.comPAS Family Advocacy: 858-260-8458Supportshow(https://www.buymeacoffee.com/maryannpetri)http://beentheregotout.com/http://www.dismantlingfamilycourtcorruption.com/Music by: mictechmusic@yahoo.comBustin' Chops & Callin' ShotsEach week Josh and Jon sit down to give their take on travel sports and everything in...Listen on: Apple Podcasts SpotifySupport the show

Slam the Gavel welcomes Lisa Breece Linke, Director Of Operations at PAS Family Advocacy, BT, CDC. Lisa is a Mental Health professional driven to help others overcome personal obstacles. She is a responsible self-starter who communicates well and is dedicated to improving the well-being of her clients. Team-oriented Behavioral Specialist with a strong track record of establishing solid relationships with her clients, co-workers and administration and local agencies, Lisa has successfully worked with diverse client population in one-on-one and group settings. Lisa is also a skilled Behavioral Specialist with an expertise in the identification and management of mental illnesses. We discussed her work at San Diego Center for Children and Residential Care, from there she went into Behavior Therapy which included the Autism community. Our discussion also included the lack of training in Social Workers, Case Workers and Guardian Ad Litem who have very little Child Development background. Fascinating discussion included 1997 ASFA, Child Trafficking with over 800,000 children gone missing. The fictitious Family Courts and that the judges are a corporate entity, a registered agent and is insured with indemnity insurance is something all litigants should explore when finding malfeasance in their case. Advice was given if CPS comes to your door as well and that caseworkers also have their own insurances. We discussed that all litigants Pro Se or otherwise get the Black's Law Dictionary which Lisa has a free PDF for parents on her web-site. To Reach Lisa: lisa@pasfamilyadvocacy.com mailto:Admin@PASFamilyAdvocacy.com mailto:CFAlawsuit@activist.com PAS Family Advocacy: 858-260-8458 Supportshow(https://www.buymeacoffee.com/maryannpetri) http://beentheregotout.com/ http://www.dismantlingfamilycourtcorruption.com/ Music by: mictechmusic@yahoo.com

Welcome back to ArtBeat Radio!  This week's installment features the collaborative efforts of students at AAW ART Center and San Diego Center in their unique musical and theatrical stories about the beach.  The first piece A Day at the Beach Feeling Fine and Sandy, features a musical story about a class field trip to La Jolla; written, recorded and produced by Service Users in San Diego Music Therapy class.  The second segment is a comedic scene called Seashells in San Jose; written acted and recorded by students in Playwriting class at ART Center.  We hope you enjoy listening and following along on this journey! Musical Beach Field Trip Story IntroductionJillian: This is our Musical Beach Field Trip story called, Day at the Beach; Feeling fine and Sandy. I hope you enjoy it! Reid: We wrote the story by brainstorming ideas together and taking turns adding words. We worked on this together in San Diego Music Therapy Class.  Stephanie: In this story, we are taking a road trip, seeing sights, eating lunch, enjoying music on the radio and enjoying each other's company. -Stephanie Max: In the background, we created a “Soundscape” by adding environmental sounds like ocean waves, cars, and elephants. We thought about what to say, and recorded our singing parts over Zoom.  Renee: It was nice to be able to take part in creating a song, interesting to write our own story, and cool to use our imagination. We hope you enjoy it.Musical Beach Story Lyrics (written and performed by Jillian, Reid, Stephanie, Renee, Juan Marcos, Max, Sarah, and Brian)It was a sunny Thursday morning, the sky was so blue, the air felt coolThe mood was so calm among the Able Arts Work Crew.  Stephanie said“We're all together at last, Isn't this great!”  “So much to do” Jillian sang, “I can hardly wait!”  Reid exclaimed, “let's seize the day!” Renee said “I want to tap beach balls and play!” Juan Marcos said, “this is too happy to miss!” Jillian said “I think we should take a Class trip, let's go the beach! So, they all hopped in the car and headed to La Jolla with their baskets.  Pumping that Art beat radio music on the way made them feel included,and through the window they saw the biggest coast that they wanted to draw. Sarah was excited as she exclaimed “I'm going to swim today!” Max sang out “We're almost there, I can smell salt in the air!”  Stephanie said, “let's stop here, I can tell fun is near… it's time to explore!” When they arrived, they were excited.  The beach was so empty!They noticed a group of elephants   eating lunch, and “thought that's so random”Then Juan Marcos got hungry, and said “I want some food.” Reid smiled and nodded, and said, “Hey, I'm hungry too.”  So, they all opened their bags, and pulled out a brownie and salad                      Poured out cool jug of water, and said cheers to the day, this has been great! Seashells in San Jose IntroductionDaniel: Wow what an awesome journey to the beach!Jillian: My favorite part was when we saw elephants; I thought that was really strange!Reid: It was amazing! The elephants were eating lunch, that's so random.Renee: Speaking of lunch dates, up next, we have a cute scene about Mickey and Minnie having their first date on the beach, titled Seashells in San JoseJuan Marcos: This script was written, acted, and recorded by students in playwriting class at ART Center.  Max: It was an exercise to learn about playwriting, so we came up with characters and settings, plot twists to turn our ideas into a story. Stephanie: We wrote it as a comedy, so we hope you have a good laugh- Stephanie

Welcome back to ArtBeat Radio!  This week's episode features the collaborative musical creations of AAW students from both San Diego Center and ART Center.  The Service Users sing and share about aspects of their experience making friends virtually, and navigating changes together as a team. Through the first piece, a parody of The Way I Am by Ingrid Michaelson, the students share a message about ways they show compassion, support, and acceptance for people they love.  Through the second original piece, Celebrate, the students cherish all of their time together by vocally and aesthetic creating a “dancy” groove.    IntroductionJillian: Welcome to this Podcast! We've been working on some new songs and parodies, we hope you like it.  This is San Diego Center and ART Center coming to you together presenting our songs that we've made.   Max: The two songs we're presenting are called The Way I Am and Celebrate.  The Way I Am is a parody and was created by San Diego Center students in music class.  Celebrate is an original song created by ART Center students in Song Creation class.  Reid: The theme for our episode is Teamwork makes the Dream Work.  It's about how we went through changes in our lives and we worked on it through Zoom together. Through teamwork, we were able to make friends from all different cities and support each other from far away.  We hope you enjoy our Mash-Up Episode.   Renee: First, we have a parody of The Way I Am, by Ingrid Michaelson, created by San Diego students in music class.  This song is about compassion, or when you feel empathy for someone.   No matter how different you are, you are important. Stephanie: We created this song to show people that we are there for them.  You can always count on us to cheer you up and be there for you.  This song is for friendships, family, and to show we love and care about them.  Hope you enjoy! The Way I Am Lyrics (performed by Reid, Renee, Jillian, Stephanie, Max, Juan Marcos, and Sarah)  If you were lonely I'll be there for you You need compassionI'll listen to you Cause I love the way you say I need you And you accept me the way I am  If you want music I'll play songs for you I'll give a tight hugTo make you happy  Cause I adore the way you show me kindnessAnd you accept me the way I am  I'll help through hard times,To show you just how much I careYou're feeling tired add ReneeThen I'll be there  Cause I appreciate you making me feel wanted And you help me the way I am And you love me the way I am And you admire me the way I am* TransitionBrian: What a great song!  It really touched my heart strings.  Up next, an original song by ART Center students called Celebrate.  This song was created in Song Creation class and it is about celebrating holidays and being with friends! Renee: We created this song by voting on different beats and vocal effects that we put together to create what you are about to hear.   Reid: When we hear this song, we start to feel “dancy” and we hope you do too!   Celebrate Lyrics (performed by Nancy, Reid, Tom (Eric), Maria R, and Aaron)  Celebrate, let's celebrateCelebrate, celebrateLet's celebrate Celebrate, let's celebrate Celebrate, celebrateLet's celebrateCelebrate, let's celebrate Memories return to me Memories return to me Ah you're going to celebrate Ah you're going to celebrate Memories return to meCelebrate, let's celebrate Let's celebrate, celebrateLet's celebrate, Let's celebrateCelebrate, CelebrateLet's celebrate, let's celebrate Celebrate, let's celebrateLet's celebrate, Let's celebrateCelebrate!    Closing Reid: What a fun song, and a great way to end our episode!   Juan Marcos: Goodbye, we hope you enjoy listening to our next episode. Jillian: Thank you for listening and please come again.  Ciao, Ciao, meow meow! 

I sat down with Lorraine Hobbs, founding director of the Youth, Family & School-based Programs at the University of California, San Diego Center for Mindfulness where she develops mindfulness-based curricula for parents, teens and children and has been a pioneer in the area of self-compassion for teens. Together, we explore how to notice the effects of stress on the kids in your life and offer them fun and useful tools for reducing it – tools that have also been shown to help children improve focus, self-control and academic performance, increase their ability to resolve conflict and improve their overall sense of wellbeing. (And they work for us grown-ups, too!)

ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses. Every year, the ASCO Annual Meeting brings together attendees from around the globe to learn about the latest research in the treatment and care of people with cancer. This year, attendees from 138 countries worldwide gathered virtually for the ASCO20 Virtual Scientific Program, held Friday, May 29 through Sunday, May 31. In the annual Research Round Up podcast series, Cancer.Net Associate Editors answer the question, “What was the most exciting or practice-changing research in your field presented at the ASCO20 Virtual Scientific Program?” In this episode, editors discuss new research in the fields of head and neck cancer and melanoma. First, Dr. Ezra Cohen will discuss new research in squamous cell carcinoma of the head and neck and adenoid cystic carcinoma. Dr. Cohen is Co-Director of the San Diego Center for Precision Immunotherapy, Associate Director of Translational Science and leads the Solid Tumor Therapeutics research program at Moores Cancer Center at UC San Diego Health. He is also the Cancer.Net Associate Editor for Head and Neck Cancers. View Dr. Cohen’s disclosures at Cancer.Net. Dr. Cohen: Hi. This is Dr. Ezra Cohen from University of California, San Diego, Moores Cancer Center. And today I'll be reviewing head/neck cancer abstracts from the American Society of Clinical Oncology Annual Meeting. I have consulted for Merck in the past. As all of us know, this meeting was virtual this year, but we had an opportunity to see the broadcasts through the virtual website. And there were a few abstracts that I thought were relevant to not only current standards of care but also to the future of research in head/neck cancer. The first one I'll talk about is a Japanese study that compared post-operative chemo radiotherapy of 3 weekly cisplatin versus weekly cisplatin in high-risk patients with squamous cell carcinoma of the head and neck. This was indeed an adjuvant trial or a post-operative trial, and really addressed an important question in the field that had been controversial and perhaps continues to be going forward. The investigators compared a dose of 40 milligrams per meter squared given every week versus the standard 100 milligram per meter squared of cisplatin given every three weeks and assess patients for local-regional control and overall survival. Interestingly enough and as opposed to some prior reports, the combination of weekly cisplatin and radiation actually proved to be superior with respect to both local-regional control and survival while providing a regimen that was fairly well-tolerated and in the aggregate actually had a lower toxicity rate than the every 3 week cisplatin, suggesting that at least at 40 mg per meter squared, we may have a regimen that is in the post-operative setting more efficacious, and better tolerated, and that it may be time to revisit standards of care or at least to perhaps accept 2 different standards of care in the post-operative setting; one being high dose every 3 weeks cisplatin and the other being weekly cisplatin. The other relevant abstract from the oral session was another randomized trial, this time from South Korea. Looking at adenoid cystic carcinoma, here patients were randomized to either receive a vascular endothelial growth factor receptor inhibitor named axitinib vs. placebo in patients with metastatic disease. This class of agents that axitinib belongs to has been noted to be active in adenoid cystic carcinoma for some time, but there had never really been any randomized trials comparing axitinib to any treatment and certainly not to observation or placebo. Fifty-seven (57) patients were enrolled and progression-free survival was the primary endpoint, in fact, 6-month progression-free survival. And what the investigators found was that this was much better in the axitinib patients versus placebo. In fact, about 70% of patients in the axitinib arm failed to progress and were still alive versus only 23% in the placebo arm. Now, this was not a large enough trial to change registration or the label of the drug, but it certainly, for patients with adenoid cystic carcinoma who have very few treatment options, does provide a therapy that now is at the very least validated through a randomized phase II trial and gives us a little bit more confidence in using this entire class of agents in patients with adenoid cystic carcinoma. One of the other targeted therapy studies that I think is also worth highlighting from the meeting was that using tipifarnib in patients with HRAS mutations. This was a study conducted across several different cancer types, but the most commonly enrolled patients and, in fact, a specific cohort were for patients with head/neck squamous cell carcinoma. And interestingly enough, the investigators having enrolled 18 patients found an overall response rate of 56%, arguably much better than we would be able to do with chemotherapy in these patients or any other targeted agent for that matter. And again, not a study that would change the label or standards of care but certainly worthwhile watching the efficacy of this agent tipifarnib going forward in patients with HRAS mutations. And then from the poster discussion session, I think we saw some interesting data that may be a prelude to the future, especially with immunotherapy. Christine Chung presented the experience of cetuximab and nivolumab, an EGFR and a PD-1 antibody in combination, and found that to be quite active, again, in a non-randomized manner but certainly enough activity to think about taking that regimen forward. Dr. Roger Cohen presented the monalizumab and cetuximab data in patients with recurrent or metastatic disease in this time in a cohort that were both platinum and PD-1 refractory, so a heavily pre-treated patient population, and very nicely finding a response rate of 20% in patients with squamous cell carcinoma in the head/neck. And then lastly, along the lines of immunotherapy, an update on the data within ICOS agonist GSK3359609 in combination with pembrolizumab in patients who were treatment naïve with head and neck squamous cell carcinoma or at least PD-1 treatment naïve and again finding some promising activity with a response rate of about 24%. The latter 2 trials, the monalizumab-cetuximab and the ICOS agonist pembrolizumab studies, are in fact now moving on to Phase III studies. And so again, there may be a change in the standard of care using some novel I-O regimens, and it's something to look out for in the future. Thank you for listening to this review of head and neck cancer abstracts at the American Society of Clinical Oncology Annual Meeting and have a nice day. ASCO: Thank you, Dr. Cohen. Next, Dr. Ryan Sullivan will discuss several studies across the field of melanoma treatment. Dr. Sullivan is a medical oncologist and Attending Physician in the Division of Hematology/Oncology at Massachusetts General Hospital. He is also the Cancer.Net Associate Editor for Melanoma and Skin Cancer. View Dr. Sullivan’s disclosures at Cancer.Net. Dr. Sullivan: My name is Dr. Ryan Sullivan. I am the associate director of the melanoma program at Massachusetts General Hospital in Boston, and I'm here today to give a summary of some exciting data that was presented at the 2020 Annual ASCO Meeting which, of course, was presented virtually. I have a few disclosures, including that I have served on advisory boards for a number of companies whose data was presented, including Bristol Myers Squibb, Merck, Novartis, and Iovance. I'd like to start, really, by thinking about how a patient's journey with melanoma begins and then moves on through various stages of treatment, because there were a number of very interesting abstracts and presentations presented this year that include important breakthroughs in many different steps in the patient's journey. The first, of course, is a diagnosis, and soon after a diagnosis, often, the next step is surgery. There's been more and more data about treatment before surgery as a way of potentially improving outcomes for patients who have a significant amount of tumor in place, typically in lymph nodes. Treatment before a planned surgery is called neoadjuvant therapy. There's also been breakthroughs, and, at this year's ASCO, updates on these breakthroughs in treatment after surgery, which is done with curative intent. We call that type of treatment adjuvant therapy. There were some updates to studies in patients who have newly diagnosed metastatic disease, and then there were some very interesting presentations about data of patients who were treated after the first type of treatment, for a patient with metastatic disease, was ineffective, demonstrating some really promising second and even third lines of treatment that may be available for patients. So I'll start with that neoadjuvant therapy. This is, again, treatment that's given before somebody who could have surgery with curative intent, and the idea behind this is to potentially improve the outcomes of patients. It's also a really important type of research treatment because we can learn a ton about how tumors respond or don't respond to certain types of treatments, and there is a really wide path that's been created by the breast cancer community, who pioneered this type of treatment, and demonstrated that new and effective therapies can actually make it to the standard of care for patients in this setting. In melanoma, we've looked at a lot of the breakthrough therapies that have been approved in the metastatic and the stage 3 after surgery setting, including immunotherapies and BRAF-targeted therapies. And the background is a number of trials have occurred, and 1 very prominent group that has been leading a lot of these efforts is the group in the Netherlands, and Dr. Christian Blank presented some data on a follow-up study of almost 100 patients, who received a combination of two drugs, ipilimumab and nivolumab, at a schedule in dosing level that had been determined to be, probably, as effective as higher doses and more toxic therapy, but had a better safety profile than other regimens. That trial was called the OpACIN-neo, which randomized patients to 3 different dosing levels and strategies. So patients receive this, and then, in a really cool fashion, they knew that almost 70 or 80% of patients would have a major response to therapy - that was based on other data - but they also wanted to see if they get away with less surgery. And so what they did was, patients who had major responses were offered a smaller surgical resection. Patients who didn't have major responses ended up having a complete surgical resection of lymph nodes, and then they just followed along. And really, it was less a trial that will prove that this is the right thing to do, but more a trial to be built upon. And as more and more data comes out, this could be a strategy that we utilize for patients, where they may only get 2 doses of a treatment, and then if they have a major response to therapy, they could just be followed closely thereafter. So this trial is called the PRADO trial. Christian Blank was the presenter, and I would say it's promising, and maybe practice-changing as more data comes out and larger trials are performed to compare this strategy with other more standard strategies. The next set of data that was presented that's really interesting is in the adjuvant setting, so again, these are patients who've had surgery to cure them of their melanoma, but they're at high risk of the melanoma coming back and so receive treatment after surgery - we call that adjuvant therapy - to reduce the chance of disease coming back. There were 2 trials that were updated at this year's ASCO. One was the KEYNOTE-054 trial. This is randomizing a drug called pembrolizumab, an anti-PD-1 blocking drug, versus placebo. This trial was a positive study, and was published a few years back, and pembrolizumab was FDA approved, a few years back, for patients who have high-risk stage 3 melanoma, who have completed surgery. The follow-up data continues to show the superiority of the pembrolizumab compared to patients who received placebo, and importantly, that superiority is across virtually every subgroup that was analyzed, and demonstrates that this approach continues to be a standard approach for patients with melanoma who are high risk and have stage 3 disease that's been resected. A similar group of patients were enrolled on to a trial called the COMBI-D study. This is a trial that randomized BRAF mutated patients with stage 3 melanoma, whose disease had been removed, and received either dabrafenib and trametinib, which is a BRAF and MEK inhibitor, or 2 placebos. Again, this trial previously read out as a "positive study,” and this regimen has been FDA approved for this patient population. Importantly, the data continues to look really good. BRAF targeted therapy, initially, it was thought that it might prevent relapse during the treatment time and a little after the treatment time, but there was thoughts that the effects of it, and the effectiveness of it, might actually wane over time, but that doesn't seem to be the case. This is a 5-year update, and it still appears that this combination is associated with cures in patients with stage 3 melanoma, who would not have been cured if they didn't receive it. So again, really important follow-up data, and strengthens the idea that this is a very reasonable alternative to anti-PD-1 antibody therapy like pembrolizumab, which was described just a few minutes before, in the same setting, but in this case in patients who had BRAF mutated melanoma. There were some important trials, and one was a retrospective study of therapy in patients who had metastatic melanoma or unresectable disease, so this is melanoma that either presented in a widespread fashion, or was previously diagnosed and treated with surgery, maybe adjuvant therapy, and then metastasized. The standard front-line therapy is really 1 of 4 options: anti-PD-1 antibody with either nivolumab or pembrolizumab; BRAF targeted therapy, if a patient has a BRAF mutation; combination nivolumab and ipilimumab; and then enrollment onto a clinical trial. Many sets of data are out there in publications about the combination of ipilimumab and nivolumab in the frontline metastatic setting, and while it is associated with the highest response rates of immunotherapy in patients with melanoma, it's also associated with very high toxicity rates. And so ultimately, a decision is typically made upfront, and we balance the risk of the toxicities with the benefit of the therapy, and a decision is made about what to give. If a patient receives ipilimumab and nivolumab in the frontline setting, and then their tumor progresses thereafter, there aren't great second-line options unless a patient has a BRAF mutation, and then BRAF targeted therapy with 1 of the 3 BRAF/MEK combinations is an option. Patients who receive single-agent PD-1 therapy second-line treatment after disease progression-- could be single-agent ipilimumab, which was the first of these new immunotherapies to be approved. And so one of the questions, though, has been could you give combination ipilimumab plus a PD-1 blocking drug in that second-line setting, and have better outcomes than if you just gave ipilimumab? There's no randomized trial looking at this, but a group in Australia did a retrospective analysis and identified patients who received either single-agent ipilimumab, or a combination ipilimumab plus a PD-1 blocking drug. I should say that I was part of this retrospective analysis, and some of our patient data was part of this analysis. What was shown was that there were improvements in the response rate for patients who received combination ipilimumab plus a PD-1 blocking drug, versus single-agent ipilimumab, and it appeared that the benefit was about twice as good, meaning the response rate was about twice as good, and patients had about twice as solid progression-free survival, and they lived twice as long. Now, any retrospective analysis is really hard to make practice-changing decisions on, we really like randomized trials that are prospective, and so that data doesn't exist. There is a randomized prospective trial currently enrolling patients in the U.S. Cooperative Group setting, and it's randomizing patients, after PD-1 blocking drugs, to either ipilimumab or a combination of ipilimumab and nivolumab. So until that trial reads out, we won't know for sure that this is the right strategy, but the data certainly was suggestive that combination ipilimumab plus the PD-1 blocking drug makes sense. There actually also was data presented in a prospective study, 1 arm, so it wasn't randomized, that patients who'd been on a PD-1 blocking drug and then switched to pembrolizumab, a PD-1 blocking drug, and a low dose of ipilimumab after their disease had progressed on the PD-1 blocking drug. In that study, response rates were in the mid-20% range - I believe it was 27% - which is higher than we've seen with ipilimumab in that setting, for which the response rate would be expected to be about 10-15%. And so again, further data this time, prospective data, suggesting that there is an improved outcome for combination therapy in the second line. Importantly, toxicity, which we worry a ton about in the frontline, seemed to be less of an issue in the second line because we'd be comparing against ipilimumab, which is more toxic as a single agent than anti-PD-1 blocking drugs is, and in the second line, it seemed like combination therapy didn't seem to be any more toxic than single-agent ipilimumab. I think we also need to see the randomized data to firmly change the standard of care forever, but I think since this is a regimen that can be offered as standard care, with commercial product, it's an option for patients, and there's now data that really supports its use. The last study I'm going to talk about is a trial of a cellular product called lifileucel. In the '80s and '90s, in the National Cancer Institute, work led by Dr. Rosenberg and his colleagues, in the surgical branch there, developed the technique where they would remove a tumor, take out the T cells from the tumor, grow the T cells, expand them, and then give them back to patients after lymphodepleting chemotherapy, which would allow patients to receive and not destroy those T cells that were coming in, and then give IL-2 to grow those T cells and support them as they expand in the body. This is a very hard therapy to receive. At the NCI, it required patients to have an initial visit, have enough tumor to have it removed, be able to come back a few weeks later, have the tumor removed, and then the T cells had to grow, and we never really knew how many patients ended up showing up at the NCI to be evaluated for this, and then, ultimately, were treated. And so it is hard to know what to make of the response rates, which were remarkably high. As high as 50-55% in some studies when looking at the data. But the worry was that maybe only a quarter of patients that showed up ended up getting treated, and so the response rate would be a lot less, of all people that were screened. And so there's real interest in finding a commercial product that could not necessarily require the production of the cell product to be done at an individual institution, and certainly not 1 institution like the NCI, but that could be done centrally and commercially. And so lifileucel is a product that comes from patients’ tumors, again, requires a patient to have surgery, the tumor gets removed; it gets sent to a central laboratory where the T cells are isolated, grown, expanded; and then when the product is ready, patients, if they're still well, are able to be admitted to the hospital get lymphodepleting chemotherapy, receive the cells, receive IL-2, and then see what happens. The data that was presented at ASCO was an update from a year ago, which showed that patients-- and all of these patients had had anti-PD-1 antibody therapy, probably 70 or 75% of patients had ipilimumab, so heavily pretreated population of patients, and the response rate of patients who were able to receive treatment was 37%. So that's not everybody, obviously, and that's not even half the patients, but that's a pretty impressive response rate, for patients who weren't previously responding to immunotherapy. There's a lot of excitement about this data, and more importantly, there was data that suggested that 82% of patients that showed up for surgery ended up getting treated. So we actually have a denominator of patients screened. Ninety-four (94%), 95% of patients were able-- a product was able to be made, so the concerns about whether or not this is for most patients that end up having surgery, the answer is they probably can make a product for just about everybody. This is probably the 1 presentation, in the oral abstract session at ASCO, in the melanoma program, that is a regimen that would be new, and potentially practice-changing in the near future. So that's exciting, and we're hopeful that that will be an option for patients in the near future. With that, I'd like to finish by saying it was another great year for the melanoma research community. Lots of really interesting data presented. I touched upon some of the highlights, but lots of other really cool trials and data presented, as well, and I remain very hopeful for the future of, not just our research community, but more importantly for our patients, who are going to benefit from this wonderful research that's being done, which will hopefully continue to lead to better outcomes for our patients. And with that, I thank you for your attention. ASCO: Thank you, Dr. Sullivan. Learn more about the research presented at the ASCO20 Virtual Scientific Program at www.cancer.net/blog, and subscribe to Cancer.Net podcasts on Apple Podcasts or Google Play for additional episodes in the Research Round Up series, released throughout the summer. This Cancer.Net podcast is part of the ASCO Podcast Network. This collection of 9 programs offers insight into the world of cancer care, covering a range of educational, inspirational, and scientific content. You can find all 9 shows, including this one, at podcast.asco.org. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds breakthrough research for every type of cancer, helping patients everywhere. To help fund Cancer.Net and programs like it, donate at conquer.org/donate.

The mental and emotional health of our youth is everything! It is our responsibility to actively participate and collaborate to ensure the overall well-being of our youth. The number of youth negatively impacted by us not being collectively proactive in their mental health is moving in the wrong direction. We must work together to change the direction now!

Dr. Andrew Friedman is an astronomer, cosmologist, and data scientist. He’s currently an NSF funded Assistant Research Scientist at the University of California at San Diego Center for Astrophysics & Space Sciences. He is also a Research Affiliate in the MIT Program in Science, Technology and Society. He holds a Ph.D. in Astronomy and Astrophysics from Harvard. We chatted about the apparent, seemingly contrived conflict between science and religion. We explored some of the sources of this conflict and how, with a good perspective, they are not really at odds. We looked at faith, both in science and religion, Gödel’s incompleteness theorem, proof of God’s existence, varying views about what God is, approaching the subject with humility, and how the Bible cannot really serve as a science textbook. Join us as we get our theology hats on.

“I’m always trying to be tranquil. I’ve experienced a lot of sadness and crisis and trauma in the last 10 years. I think there is a part of me that could have gone that direction and you would have been able to see it in my work. I have done some small pieces where they do look angry. But as far as the larger pieces, I would always feel like if I was working on something that gave that message that it didn’t really calm me. It didn’t really work for me as art therapy which is at the time what I wanted it to do. I wanted it to be able to take me to a quiet place. A thoughtful place. I wanted it to be about love and community, not anger or separation.” Watercolor artist and teacher Jan Heaton is this weeks guest. We met seven years ago when I was working on a photo project capturing artists in their spaces. That experience enhanced my desire to spend more time with creative people and explore their lives and work. Our conversation covers her creative childhood and her art and teaching career through until present day, which is typical of my interviews. But the main impetus for this episode is to share her late daughter Kristin’s story and the upcoming Davis Gallery group exhibition and fundraiser that celebrates her life. https://files.fireside.fm/file/fireside-uploads/images/4/41335247-836c-4f4a-8a8b-aeca55f3227a/ybvMByuv.jpg Pink - 60" x 40" - Watercolor on paper Big Pink Blanket of Love Work by Jan Heaton & Friends Opening reception: Saturday, September 14th | 7-9 pm September 14 – October 12 Davis Gallery & Framing 837 W. 12th Street Austin, TX78701 Hours: Mon-Fri 10am-6pm | Sat 10am-4pm 512-477-4929 In partnership with the Peabody Fund and Dell Children’s Medical Center, Davis Gallery is honored to announce a unique group show in support of Davis’ own Jan Heaton, one of Austin’s premier watercolorists. In February of 2019 Jan’s daughter, Kristin Peabody, was taken by an aggressive cancer she had battled for ten years. In place of the solo exhibition that was scheduled for Jan, Davis Gallery and Austin’s artistic community are banding together in solidarity to fight cancer and find strength. Over sixty artists have contributed 4x4 inch squares of their own original artwork in an overall pink palette that will be hand-stitched together to create a pink quilt, symbolizing the community’s compassion, strength, and friendship. The idea for the pink quilt is derived directly from Kristin's feeling that the love she had been shown over the course of her treatments felt like a "big, warm, pink blanket of love". In addition to this collaborative quilt, an extended group show focused on love, gratitude, and family will feature original artwork by Jan Heaton and over twenty other artists. Ten percent of the proceeds raised during this four weeklong exhibit will be donated to the Peabody Fund, a project set up in direct response to Kristin Peabody’s ambition to help develop innovative work in cancer research through the San Diego Center for Personalized Immunotherapy. The “big pink blanket of love” collaborative quilt will be donated to the Dell Children’s Medical Center’s fundraiser, “The Art of Giving”, an annual fundraiser dedicated to providing art and music therapy for thousands of young cancer patients. https://files.fireside.fm/file/fireside-uploads/images/4/41335247-836c-4f4a-8a8b-aeca55f3227a/7jt4o45Q.jpg Panorama of Jan from 2013 when we met. Artist statment courtesy of Jan's website My paintings are personal observations of color, movement, relationships and forms in nature. I prefer the watercolor medium, as I love paper, and the tactile manner in which the pigment integrates with the paper. Painting on cold pressed 100% cotton paper I patiently build translucent, veiled layers of color, allowing the forms and values to evolve in a detailed and orchestrated manner. I normally work in a series, which permits the wet color to dry thoroughly between layers. The images are not restricted by the paper’s edges. Every random mark is there because it needs to be there. The reputed “happy mistakes” (that watercolor legend reports often occur in this medium) are planned and controlled. The circular orbs in my current work are simple, bold, direct, sensual, playful and often mysterious. The sphere recalls harmony, rhythm, movement, patterns, and boundless symbolic metaphors. In my work the circle exists independently and in groups, referencing water patterns on a shore, or a rising moon, rounded fruits, or the shape of a flower. The circle reminds me of family and friends, who are very important to my creative process. The times spent in a circle, talking, eating, dancing, playing, telling stories and solving the problems of everyday life. The memories of this connection to the circle are important to me. My intention is not to impose a specific message to the viewer. I often hesitate to title my paintings, for fear that they will be translated only according to my vision and close a door to the viewer’s interpretations. I hope my paintings will allow the viewer to observe a familiar object in a new way. https://files.fireside.fm/file/fireside-uploads/images/4/41335247-836c-4f4a-8a8b-aeca55f3227a/pM0JVI7r.jpg Panorama with Jan at Boggy creek farmstand in 2014. Some of the subjects we discuss: How we met Panorama project Farmers market series Ideas & editing inspiration Mary Oliver poetry Detroit childhood Jan’s parents Artistic family Calligraphy Thank you notes Various jobs Deadlines Painting/website Losing job/new path Approaching galleries Jace Graf portfolio Wally Workman Gallery representation Hiatus Spa/calming work Morning walk/looking Boundaries/introversion Validation/feedback Discipline/schedule The Art of Giving Elizabeth Hendley Art Therapy Being a teacher What is watercolor? Opportunities/learning Advertising experience Business of art Kristin’s story The Peabody Fund Davis Gallery exhibition Personalized cancer vaccine This interview 2nd/3rd opinions Medical advocacy Supportive friends & family What’s different Gratitude This interview has been edited and condensed for clarity. Intro music generously provided by Stan Killian (http://stankillian.com/main/) Support this podcast. (http://www.austinarttalk.com/supportpodcast)

Dr. Andrew Friedman is an astronomer, cosmologist, and data scientist. He’s currently an NSF funded Assistant Research Scientist at the University of California at San Diego Center for Astrophysics & Space Sciences. He is also a Research Affiliate in the MIT Program in Science, Technology and Society. He holds a Ph.D. in Astronomy and Astrophysics from Harvard. We chatted about how science fiction inspired him as a youth to become a cosmologist. Also, how important it is to have a Ph.D. thesis advisor who’s enthusiastically supportive. Then, we got into some cool topics of cosmology: using Type Ia supernovae to measure the rate of expansion of the universe, why infrared observations of those stars are helpful, whether quantum entanglement suggests a substrate on which spacetime resides, the multiverse, and the implications of the Planck length and Higgs field for our very existence.

Kristi Worley, Director of Philanthropy for the San Diego Center for Children, is joined by her colleagues, Linda Katz, Co-Chair of the Center’s 132nd Anniversary Celebration, and Sundiata Kata, the organization’s Music Director. Worley chats about Center’s long history of mental health expertise; Katz discusses the Saturday, May 11 Anniversary Celebration that will be held at Humphrey’s by the Bay; and Kata talks about his 50-year career at the Center.

Gürol Süel is a Professor of Molecular Biology and the Associate Director of the San Diego Center for Systems Biology. His research team integrates quantitative biology approaches with mathematical modeling to identify principles of bacterial organization and coordination. Most recently, the team discovered a new form of bacterial communication that arises in biofilms: Ion channel mediated electrical signaling. For more context on this discovery, please read this article in The Atlantic Magazine.

Spiritual talk given on June 4, 2017 at the Santa Barbara Vedanta Temple by Swami Harinamananda, visiting from the San Diego Center. The effects of the three gunas(Satva, Rajas and Tamas), the different states of mind which operate in all of us, are explored in this talk. We learn to be aware of which quality is acting at different times, how it influences our actions, and how our actions can change the operative guna when we choose to do so. Excellent talk!